Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.76 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.76 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15516162 | 1.00 | SLC6A3 (0.76) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7088802 | 1.00 | SLC6A3 (0.76) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7291113 | 0.92 | SLC6A3 (0.65) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7291105 | 0.92 | SLC6A3 (0.65) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL9405548 | 0.90 | SLC6A3 (0.74) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL9405547 | 0.90 | SLC6A3 (0.74) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL9405598 | 0.90 | SLC6A3 (0.74) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6792848 | 0.89 | SLC6A3 (0.72) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7288922 | 0.89 | SLC6A3 (0.74) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7288917 | 0.89 | SLC6A3 (0.74) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2568805-B1 | A MEDICAL FLUID, A METHOD OF TREATMENT AND USE OF THE FLUID | XVIVO PERFUSION AB (SE) | 2019-05-01 | — | — | EP | claimed |
| US-20160354359-A1 | COMPOSITION COMPRISING NOR-ADRENALINE AND A NET INHIBITOR FOR ADMINISTERING TO A BRAIN-DEAD, HEART-BEATING POTENTIAL ORGAN DONOR | XVIVO PERFUSION AB (SE) | 2016-12-08 | — | — | US | claimed |
| EP-2568805-B1 | A MEDICAL FLUID, A METHOD OF TREATMENT AND USE OF THE FLUID | XVIVO PERFUSION AB (SE) | 2019-05-01 | — | — | EP | disclosed |
| US-10271540-B2 | Medical fluid, a method of treatment and use of the fluid | XVIVO PERFUSION AB (SE) | 2019-04-30 | — | — | US | disclosed |
| US-20160354359-A1 | COMPOSITION COMPRISING NOR-ADRENALINE AND A NET INHIBITOR FOR ADMINISTERING TO A BRAIN-DEAD, HEART-BEATING POTENTIAL ORGAN DONOR | XVIVO PERFUSION AB (SE) | 2016-12-08 | — | — | US | disclosed |
| US-20160338343-A1 | MEDICAL FLUID, A METHOD OF TREATMENT AND USE OF THE FLUID | XVIVO PERFUSION AB (SE) | 2016-11-24 | — | — | US | disclosed |
| US-20130065218-A1 | MEDICAL FLUID, A METHOD OF TREATMENT AND USE OF THE FLUID | VIVOLINE MEDICAL AB (SE) | 2013-03-14 | — | — | US | disclosed |
| US-6350758-B1 | NOVEL ANALOGS OF COCAINE, ENHANCED ANALGESIC AND/OR VASOCONSTRICTIVE PROPERTIES, INHIBIT THE UPTAKE OF DOPAMINE OR SEROTONIN SO USEFUL FOR TREATING PARKINSON'S DISEASE, DEPRESSION, OR OBESITY, TREATING COCAINE ABUSE, COCAINE | GEORGETOWN UNIVERSITY | 2002-02-26 | — | — | US | disclosed |